PARP1 and neoplasm: The MDM2-based PROTACs, although still under-represented within the universe of PROTACs, have unique and very advantageous anti-tumor characteristics, given that, in addition to degrading proteins, such as the AR [20], BCR4 [67], PARP1 [68], or their own MDM2 [65], they have the ability to activate the p53 tumor suppressor pathway.